PHASE 3 DEVELOPMENT
There are many compounds in development for the management of NASH. It is very important to understand the path to regulatory approval
Prof. Arun Sanyal
Learn from the expertise of Professor Arun Sanyal, a distinguished hepatologist and professor of medicine at Virginia Commonwealth University. Discover his valuable insights on NASH and liver fibrosis through his video contributions to PanNash.
Read MorePHASE 3 DEVELOPMENT
NASH is Part of a Multi-System Disorder
Prof Sanyal, USA, reminds us that NAFLD is the most common liver disease and reviews the comorbidities associated with NAFLD, and particularly the association with cardiovascular disease.
Phase 3 development in the field of non-alcoholic steatohepatitis (NASH)
Prof. Arun Sanyal (USA) talks about and explores phase 3 development in NASH as part of the PanNash initiative as well as drug development and so on